Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker

Open, Parallel, Single-Site Study to Evaluate Sensitivity and Specificity of Newly Defined Diagnosed-biomarker for Gastric Cancer Pts and Cancer-free Healthy Volunteers

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02848066

Enrollment

353

Registered

2016-07-28

Start date

2015-07-31

Completion date

2017-09-30

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

The purpose of this study is to evaluate sensitivity and specificity of newly defined tumor biomarker with gastric cancer pts and cancer-free healthy volunteers.

Detailed description

Measurements of specific glycosylation changes in serum haptoglobin.

Interventions

PROCEDUREBlood sample(10cc) collection

In both groups, serum haptoglobins to be collected and analyzed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

Arm1 (Gastric cancer patient) 1. Inclusion Criteria: * Male or female over 19 years * Patients with histologically Gastric Cancer (included Gastroesphageal junction) * Primary gastric cancer or/and metastatic gastric cancer. * Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted 2.

Exclusion criteria

* Prior or present history of malignancies other than gastric cancer * Any condition that confounds the ability to interpret data from the study under the investigational confirmed. Arm2 (Cancer-free healthy volunteers) 1. Inclusion Criteria: * Male or female over 19 years * Cancer-free status. * Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted 2.

Design outcomes

Primary

Measure	Time frame
AUC(Area Under the Curve)	through study completion, an average of 1 year

Secondary

Measure	Time frame
Relative abundance of glycosylations	through study completion, an average of 1 year

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026